

Synthesis and structure of novel 4,5-dihydro-1*H*-pyrazoles: salicylic acid based analgesic agents

Pablo Machado,^a Fernanda A. Rosa,^a Marcelo Rossatto,^a Gabriela da S. Sant'Anna,^b Patricia D. Sauzem,^b Rubia M. Siqueira da Silva,^a Maribel A. Rubin,^b Juliano Ferreira,^b Helio G. Bonacorso,^a Nilo Zanatta,^a and Marcos A. P. Martins^{a*}

^a*Núcleo de Química de Heterociclos (NUQUIMHE), Departamento de Química, Universidade Federal de Santa Maria, 97105-900, Santa Maria, RS, Brazil*

^b*Laboratório de Neurotoxicidade e Psicofarmacologia, Departamento de Química, Universidade Federal de Santa Maria, 97105-900, Santa Maria, RS, Brazil*

E-mail: mmartins@base.ufsm.br

Abstract

An efficient method to obtain 4-alkoxy-2-oxo-but-3-enoic acid ethyl esters [EtO₂CC(O)C(R²)=C(R¹)OR, where R = Me, Et; R¹ = Me, Ph, 4-MeC₆H₄, 4-BrC₆H₄, 4-FC₆H₄; R² = H, Me] from the acylation of enol ethers or acetals with ethyl oxalyl chloride is reported. The cyclocondensation reaction of these substrates and their trifluoromethylated analogues [CF₃C(O)C(R₂)=C(OR)R¹] with salicylic hydrazide furnished a series of ethyl 5-hydroxy-1-(2-hydroxybenzoyl)-4,5-dihydro-1*H*-pyrazole-5-carboxylates and 5-hydroxy-5-trifluoromethyl-4,5-dihydro-1*H*-1-(2-hydroxybenzoyl) pyrazoles, respectively. The structure of the compounds was supported by crystallographic data. Orally administrated, one of each of the series of pyrazoles (R² = H, R¹ = Me) showed significant analgesic effects in the writhing test in mice. The decrease in pain-related behavior obtained was close to that achieved with aspirin activity.

Keywords: Pyrazoles, enones, salicylic acid, X-ray, analgesia

Introduction


The synthesis of pyrazole and its analogues has been a subject of consistent interest because of the wide range of applications for such heterocycles in the pharmaceutical and agrochemical industries.¹ Therefore, extensive research efforts are continually directed at the discovery of new heterocycles with appropriate pharmacological effects. Among their range of properties, the compounds containing a pyrazole scaffold have been shown to exhibit HIV-1 reverse transcriptase and IL-1 synthesis inhibition, as well as antihyperglycemic, antibacterial, sedative-hypnotic, anti-inflammatory, antipyretic and analgesic activity.² In part, the anti-inflammatory,

antipyretic and analgesic properties of pyrazole derivatives have been associated with the inhibition of prostaglandin biosynthesis in the cyclooxygenase step.³ However, their analgesic effects may involve other mechanisms, such as the release of endogenous opioids,⁴ the modulation of nitric oxide production,⁵ and the inhibition of excitatory amino acid receptors.⁶

The synthesis of pyrazole derivatives has been well explored using the so-called [3+2] atom fragments, where β -diketones or α,β -unsaturated ketones are used as the 3-atom building block and hydrazines as the 2-atom fragment. In the last decade, our research group has reported the general synthesis of 1,1,1-trihalo-4-alkoxy-3-alken-2-ones, 3-atom building blocks, and demonstrated their usefulness in heterocyclic preparations.⁷ In addition, 1,1,1-trichloro-4-alkoxy-3-alken-2-ones have been found to be powerful precursors for the synthesis of carboxyl derivative heterocycles, as the trichloromethyl group undergoes a hydrolysis reaction when treated with either alcohols, sulfuric acid (96%) or their mixture in water.⁸ However, the use of unsymmetrically substituted precursors often leads to a mixture of regioisomers hindering the use of this method for regiospecifically obtaining the carboxyalkylpyrazole derivatives by a one-pot procedure.⁹ Thus, we became interested in a 1,3-dielectrophilic precursor, already substituted with a carboxyalkyl group, aiming toward a more general, efficient and regiospecific synthesis of such heterocyclic compounds. With regards to the synthesis of carboxylpyrazoles, other methods and precursors have been found in the literature,¹⁰ however, they have been reported to present disadvantages, mainly due to their limited scopes and the use of substrates not readily available. We thus decided that the reported acylation^{11a} of enol ethers with ethyl oxalyl chloride deserved reinvestigation as a general method to synthesize 4-alkoxy-2-oxo-3-butenic esters (1,3-dielectrophilic compounds), because of the simplicity of the procedure. Another method that has been performed for the synthesis of compounds such as **2a** (Scheme 2), consists in the methylation of ethyl 2,4-dioxopentanoate with diazomethane. However, this method showed serious problems, such as a mixture of isomers, low yields and also the limitation of the synthesis of only one compound.^{11b} Furthermore, an analogous to compound **2b** (Scheme 2) has also been reported in the literature, this compound showing an ethoxy instead of a methoxy group at the 4 position of the 4-alkoxy-2-oxo-3-butenic ester.^{11c}

In addition, as part of our research program, we were interested in obtaining compounds endowed with anti-inflammatory, antipyretic and mainly analgesic activity. Our contributions in this field include the investigation of novel pyrazole derivatives in animal models of inflammation, fever and pain.¹² In that study, the presence of 5-trihalomethyl-4,5-dihydro-1*H*-pyrazole^{12a-d} as well as of a 5-ethoxycarbonyl pyrazole^{12e} ring were a determining factor in obtaining compounds with good antipyretic and analgesic properties against neurogenic, inflammatory and visceral pain in rodents. Thus, considering the analgesic efficacy of 4,5-dihydro-1*H*-pyrazoles, we intend to explore the hypothesis that their *hybridization* with salicylic acid can supply the design of novel potent analgesic agents (Scheme 1). Salicylic acid is known to present numerous therapeutic applications such as: anti-arthritic, antineuralgic, antirheumatic, anti-thrombotic, keratolytic, antiseptic, anti-inflammatory, antipyretic and analgesic activity.¹³ Therefore, the hybridization of these two scaffolds, which share analgesic and antipyretic

properties, may contribute in a synergistic manner to bring about an evolution of activity in a second-generation of molecules.¹³




Scheme 1

Results and Discussion

The acylation of enol ethers **1a,f** with ethyl oxalyl chloride (Scheme 2) in pyridine was carried out with an equal molar ratio using anhydrous chloroform as solvent. The most satisfactory results were obtained when the reactions were performed at between 0°C and room temperature for 16h (**2f**) or from 0°C to 35°C for 18h (**2a**).

In an attempt to expand the scope of the reaction by making use of observations made previously in our laboratory,¹⁴ we also performed the acylation of acetophenone acetals **1b-e** with ethyl oxalyl chloride. This activated acyl halide reacted with the enol ethers, generated *in situ* from the respective acetals, furnishing the 4-Aryl-4-methoxy-2-oxo-3-butenic esters **2b-e** as a one-pot procedure in good yields. This reaction was carried out using acetal, pyridine and the acylating agent at a molar ratio of 1:2:2, in reflux of chloroform for 5 h. The second equivalent of acylant trapped the methoxyl group, liberated from acetal, forming methyl ethyl oxalate, which was separated from the product by distillation. The acetals **1b-e** were synthesized from the reaction of the respective ketone with trimethyl orthoformate in the presence of *p*-toluenesulfonic acid.¹⁵



1,2	a	b	c	d	e	f
R	Me	-	-	-	-	Et
R ¹	Me	Ph	4-MeC ₆ H ₄	4-BrC ₆ H ₄	4-FC ₆ H ₄	H
R ²	H	-	-	-	-	Me

(i) R²CH=C(OR)R¹ (**1a, f**), CHCl₃, Py, 0° to 35°C, 16-18 h

(ii) CH₃C(OMe)₂R¹ (**1b-e**), CHCl₃, Py, 0° to 65°C, 5 h.

Scheme 2

The ¹H and ¹³C NMR spectra of products **2a-f** showed sets of signals corresponding to the proposed structures with the vinylic hydrogen (H-3) at a range of δ 6.13-7.59. The ¹³C NMR showed two typical signals assigned to the vinylic carbons on average at δ 102.5 (C-3) and 172.0 (C-4).

On the basis of X-ray experiments, it was established that the methoxy [O(10)-C(11)] and the carbonyl group [C(6)-O(7)] were situated *trans* to one another on the double bond ((*E*-configuration, Figure 1) with a torsional angle of 172.6(15)° in the synthesized compound **2e**.

In a second step, our efforts were focused on the synthesis of new salicylate-containing dihydropyrazoles and on the validation of the method of *hybridization* used for obtaining compounds endowed with analgesic activity. Although some trifluoromethyl salicylate-containing dihydropyrazoles have been described in the literature,¹⁶ the presence of this moiety has been justified due to the unique physical and biological properties of fluorine when attached to drug-like compounds.^{17a} In many systems, the substitution of the methyl group by a trifluoromethyl group, for example, results in added lipophilicity [π (CF₃) = 1.07 versus π (CH₃) = 0.50],^{17b} which may lead to easier absorption and transportation of the molecules within biological systems and thereby improve the overall pharmacokinetic properties of the compounds.

The synthetic procedure for the preparation of such compounds employed two simple protocols: (i) the reaction of methyl salicylate with hydrazine hydrate to give the corresponding hydrazide and (ii) the cyclocondensation reaction of the hydrazide **4** with appropriate α,β -unsaturated ketones **2,5** (Scheme 3). The salicylic hydrazide **4** was readily available from the reaction of hydrazine hydrate with ester **3** in reflux of anhydrous ethanol for 5 h, in accordance with the previously reported procedure.¹⁹ The crystalline product was isolated in good yield (78%). The second step was carried out from the cyclocondensation of previously synthesized 4-

alkoxy-2-oxo-3-butenic esters **2** and 4-alkoxy-1,1,1-trifluoro-3-alken-2-ones **5** with salicylic hydrazide **4**.





Figure 1. ORTEP¹⁸ obtained from crystal structure of (*E*)-4-(4-fluorophenyl)-4-methoxy-2-oxo-but-3-enoic acid ethyl ester (**2e**). Displacement ellipsoids are drawn at the 50% probability level.

The 4-alkyl(aryl)-1,1,1-trifluoro-3-alken-2-ones **5a-f** were synthesized from the reaction of the respective enol ether (**1a,f**) or acetal (**1b-e**) with trifluoroacetic anhydride according to previous publications.²⁰ The reaction of α,β -unsaturated ketones **2,5** with salicylic hydrazide was conducted in the presence of methanol or ethanol at reflux for 16 h. The 4,5-dihydro-1*H*-pyrazoles **6,7** were obtained regioselectively with satisfactory yields (60–96%). As can be verified from extensive reports from our laboratories,^{7a} the 4,5-dihydro-1*H*-pyrazoles were highly stable and could be isolated. In most cases, these compounds were obtained when the N-1 or C-5 was substituted by a strong electron-withdrawing group that hindered the elimination of water and a subsequent aromatization of the pyrazole ring.^{1a,7a} In the present study, we synthesized compounds that possessed in their structures a combination of effects that avoided the dehydration reaction: a 2-hydroxybenzoyl group attached on N-1 and an ethyl carboxylate or trifluoromethyl group on C-5.

Pyrazoles **6,7** showed sets of ¹H and ¹³C NMR data that corresponded to the proposed structures. Compounds **6a-e** and **7a-e** showed ¹H NMR chemical shifts of the diastereotopic methylene protons (H-4a and H-4b) as a characteristic AB system and as a doublet at the range of δ 2.97 – 3.55 and another doublet at the range δ 3.20 – 3.75, respectively, with a geminal coupling constant at the range of ²*J* = 18 – 19 Hz. The ¹³C NMR spectra showed typical chemical shifts of 4,5-dihydro-1*H*-pyrazole rings on average at δ 157.0 (C-3), 46.4 (C-4), 88.4 (C-5, **6a-f**), 91.2 (C-5, **7a-f**), 168.2 (CO₂Et), 123.5 (CF₃). It is noteworthy that C-5 showed similar chemical shifts for series **6** and **7**, emphasizing the similarity of the negative inductive effect of ethyl carboxylate and the trifluoromethyl group.



	2,6	5,7							
R ³	CO ₂ Et	CF ₃	2,5,6,7	a	b	c	d	e	f
			R	Me	Me	Me	Me	Me	Me
			R ¹	Me	Ph	4-MeC ₆ H ₄	4-BrC ₆ H ₄	4-FC ₆ H ₄	H
			R ²	H	H	H	H	H	Me

(i) NH₂NH₂•H₂O, EtOH, reflux, 5h

(ii) EtO₂CC(O)C(R²)=C(R¹)OR (**2a-f**) or CF₃C(O)C(R₂)=C(OR)R¹ (**5a-f**), MeOH (EtOH), reflux, 16h

Scheme 3




Figure 2. ORTEP¹⁸ obtained from crystal structure of Ethyl 3-(4-fluorophenyl)-5-hydroxy-1-(2-hydroxybenzoyl)-4,5-dihydro-1*H*-pyrazole-5-carboxylate (**6e**) and 3-(4-Fluorophenyl)-5-hydroxy-5-trifluoromethyl-4,5-dihydro-1*H*-1-(2-hydroxybenzoyl)pyrazole (**7e**). Displacement ellipsoids are drawn at the 50% probability level.

¹H and ¹³C NMR data of compounds **6f** and **7f** showed that only one pair of the diastereoisomers was obtained. Semi-empirical AM1 calculations²¹ showed that the diastereoisomer pair *5S4R/5R4S* were 1.95 kcal.mol⁻¹ (**6f**) and 1.52 kcal.mol⁻¹ (**7f**) more stable than the diastereoisomer pair *5S4S/5R4R*. These data are supported by previously reported crystallographic studies from analogous compounds.²² The difference in energy between the two

pairs of diastereoisomers suggests that the formation (> 93%) of compounds **6f** and **7f** supply the hydroxyl and methyl group situated *cis* to one another.

The structures of compounds **6e** and **7e** were also supported by crystal X-ray diffraction (Figure 2). These crystallographic studies confirmed the existence of hydrogen bonds involving the 2-hydroxybenzoyl moiety that was suggested from the downfield peak (broad) of the phenol proton (around 10.5 ppm) in the ^1H NMR. The intramolecular hydrogen bonds generated two six membered rings where O---H bond distances of 1.76 Å [O(25)-H(25)---O(19)], 2.45 Å [O(5)-H(5)---O(19)] and 1.82 Å [O(23)-H(23)---O(17)], 2.25 Å [O(5)-H(5)---O(17)] were observed for structures **6e** and **7e**, respectively. As expected, the sum of the internal angles of the tetrasubstituted pyrazole rings [N(1)-N(2)-C(3)-C(4)-C(5)] suggested the planarity of this structure since values of 539.21° and 539.49° were found for compounds **6e** and **7e**, respectively, deviating slightly from the ideal value of 540°. The crystal Data and selected bond lengths and angles are summarized and shown in Tables 1 and 2.²³

In an attempt to validate our hybridization method, the analgesic activity of compounds **6a** and **7a** was evaluated by the acetic acid writhing test in mice as previously described.²⁴ In this classic test, the intraperitoneal administration of 0.8% of acetic acid (10 mL/Kg) causes a writhing (stretching) behavior in the animal which is interpreted as its pain response.

The number of writhing responses was then counted over a period of 10 min. In addition, the locomotor activity of the animals was evaluated on a rotarod apparatus. The compounds tested did not alter rotarod performance (data not shown) suggesting that they did not induce any form of gross motor impairment.

Oral administration of compounds **6a** and **7a** (500 $\mu\text{mol/Kg}$) caused a significant analgesic effect in the writhing test (Figure 3). This effect was similar to that obtained with the analgesic activity presented by aspirin, a classical salicylate derivative in clinical use, as no significant difference between aspirin and compounds **6a** and **7a** was observed. Among the 4,5-dihydro-1*H*-pyrazoles tested, the first insight obtained was that compound **7a** presented better efficacy than **6a**.




Figure 3. Effect of aspirin (ASP), **6a** and **7a** on the number of writhes induced by acetic acid in mice. Data are reported as means \pm S.E.M., $n = 9-12$ per group. * $P < 0.001$ [$F(3,4) = 6.20$] compared with 5% Tween 80 (Vehicle).

Table 1. Crystallography data and refinement method for compounds **2e**, **6e** and **7e**

Crystal Data	2e	6e	7e
CCDC N°	628316	628318	628317
Molecular formula	C ₁₃ H ₁₃ FO ₄	C ₁₉ H ₁₇ F N ₂ O ₅	C ₁₇ H ₁₂ F ₄ N ₂ O ₃
Temperature	294(2) K	294(2) K	100(2) K
Color	Translucent	Translucent	Translucent
Crystal size (mm)	0.38 x 0.20 x 0.08	0.265 x 0.155 x 0.063	0.34 x 0.21 x 0.07
Symmetry	Monoclinic, <i>P2(1)/c</i>	Triclinic, <i>P-1</i>	Monoclinic, <i>P2(1)/n</i>
Unit cell dimension (Å, °)	<i>a</i> = 9.6087(3) α = 90°. <i>b</i> = 15.8346(6) β = 106.352(2)°. <i>c</i> = 8.5386(4) γ = 90°.	<i>a</i> = 11.1283(3) α = 97.330(2)°. <i>b</i> = 13.0144(4) β = 109.249(2)°. <i>c</i> = 14.4799(4) γ = 108.443(2)°.	<i>a</i> = 10.9400(5) α = 90°. <i>b</i> = 9.6633(4) β = 96.689(2)°. <i>c</i> = 14.6722(7) γ = 90°.
Volume (Å ³ , <i>Z</i>)	1246.60(8), 4	1814.13(9), 2	1540.54(12), 4
<i>D_c</i> (g·cm ⁻³), <i>F</i> (000)	1.344, 528	1.363, 776	1.588, 752
μ (mm ⁻¹)	0.109	0.106	0.142
θ range for data collection	3.58 to 28.28°	2.10 to 28.36°	3.50 to 27.47°
Reflections collected	13234	40598	15713
Independent reflections (<i>R_{int}</i>)	3087 (0.0302)	9020 (0.0599)	3511 (0.0408)
Completeness to θ	99.8 %	99.4 %	99.5 %
Solution	Direct methods SHELXS-97	Direct methods SHELXS-97	Direct methods SHELXS-97
Refinement method	Full-matrix least-squares on <i>F</i> ²	Full-matrix least-squares on <i>F</i> ²	Full-matrix least-squares on <i>F</i> ²
Data / restraints / parameters	3087 / 12 / 185	9020 / 0 / 493	3511 / 0 / 235
Goodness-of-fit on <i>F</i> ²	1.086	0.827	0.916
Final <i>R</i> indices [<i>I</i> > 2σ (<i>I</i>)]	<i>R</i> 1 = 0.0446, <i>wR</i> 2 = 0.1337	<i>R</i> 1 = 0.0452, <i>wR</i> 2 = 0.1178	<i>R</i> 1 = 0.0387, <i>wR</i> 2 = 0.0936
<i>R</i> indices (all data)	<i>R</i> 1 = 0.0756, <i>wR</i> 2 = 0.1441	<i>R</i> 1 = 0.1453, <i>wR</i> 2 = 0.1409	<i>R</i> 1 = 0.0671, <i>wR</i> 2 = 0.1005

Table 2. Selected bond length (Å), bond angles (°) and torsional bond angles (°) for compounds **2e**, **6e** and **7e**

Compound 2e		Compound 6e		Compound 7e	
F(1)-C(15)	1.366(17)	N(1)-N(2)	1.392(2)	N(1)-N(2)	1.401(17)
C(4)-C(6)	1.538(2)	N(1)-C(5)	1.480(2)	N(1)-C(5)	1.491(19)
C(8)-C(9)	1.354(2)	N(2)-C(3)	1.286(2)	N(2)-C(3)	1.286(18)
C(6)-O(7)	1.2123(16)	C(3)-C(4)	1.501(3)	C(3)-C(4)	1.493(2)
C(9)-O(10)	1.3428(17)	C(4)-C(5)	1.525(3)	C(4)-C(5)	1.535(2)
O(10)-C(9)-C(8)	122.88(13)	C(5)-C(6)	1.537(3)	C(5)-C(6)	1.537(2)
O(10)-C(9)-(C12)	109.31(12)	C(5)-O(5)	1.395(2)	C(5)-O(5)	1.401(18)
O(7)-C(6)-C(8)	128.12(14)	N(2)-N(1)-C(5)	112.83(16)	N(2)-N(1)-C(5)	111.79(11)
C(9)-C(8)-C(6)	126.42(13)	C(3)-N(2)-N(1)	107.83(16)	C(3)-N(2)-N(1)	108.52(12)
O(7)-C(6)-C(4)	118.01(13)	N(2)-C(3)-C(4)	114.12(18)	N(2)-C(3)-C(4)	114.37(14)
O(5)-C(4)-C(6)	124.06(14)	C(3)-C(4)-C(5)	103.01(16)	C(3)-C(4)-C(5)	103.07(12)
O(5)-C(4)-O(3)	123.8(3)	N(1)-C(5)-C(4)	101.42(15)	N(1)-C(5)-C(4)	101.74(12)
C(8)-C(9)-C(12)- C(17)	-52.0(2)	O(19)-C(19)-N(1)- N(2)	177.65(17)	N(2)-N(1)-C(17)- O(17)	- 165.49(14)
O(5)-C(4)-C(6)- O(7)	- 170.02(17)	C(21)-C(20)-C(19)- N(1)	-4.0(3)	N(1)-C(17)-C(18)- C(19)	-3.7(3)
O(10)-C(9)-C(12)- C(13)	-47.35(18)	N(2)-C(3)-C(31)- C(36)	5.9(3)	N(2)-C(3)-C(31)- C(36)	8.8(2)

In summary, a simple and efficient method for the synthesis of 4-alkoxy-2-oxo-3-butenic esters was reported. Regiospecific cyclocondensation of these substrates and their trifluoromethylated analogues with salicylic hydrazide led to the 4,5-dihydro-1*H*-pyrazole derivatives in good yields. In addition, the structures of these series of compounds were also supported by crystallographic studies. The hybridized compounds **6a** and **7a** showed interesting analgesic activity in mice, validating this design for the construction of novel analgesic agents. Further investigations are in progress to elucidate the structural requirements for the analgesic effect of this class of compounds, as well as their action on other models of pain. Finally, our preliminary findings showed the synthesized 4,5-dihydro-1*H*-pyrazole derivatives as promising prototypes for the treatment of states of pain.

Experimental Section

General Procedures. Unless otherwise indicated, all common reagents were used as obtained from commercial suppliers without further purification. The solvents were dried and purified according to recommended procedures.²⁵ All melting points were measured using a Reichert-Thermovar apparatus and are uncorrected. Yields listed are of isolated compounds.

¹H and ¹³C NMR spectra were acquired on a Bruker DPX 200 or Bruker DPX 400 spectrometer (¹H at 200.13 MHz or 400.13 MHz and ¹³C at 50.32 MHz or 100.63 MHz, respectively) at 300 K, in 5 mm sample tubes, and with a digital resolution of ± 0.01 ppm. CDCl₃, or DMSO-*d*₆ were used as solvents containing TMS as internal standard. Mass spectra were registered in a HP 5973 MSD connected to a HP 6890 GC and interfaced by a Pentium PC. The GC was equipped with a split-splitless injector, autosampler cross-linked HP-5 capillary column (30 m, 0.32 mm of internal diameter), and helium was used as the carrier gas. IR spectra were obtained with a Bruker Tensor 27 spectrometer using films or KBr pellets of the compounds. The crystal data were recorded on a Bruker Kappa Apex II CCD area detector with graphite monochromatized Mo K _{α} radiation ($\lambda = 0.71073$ Å). The data were processed with SAINT and SADABS. The structure was solved by direct methods (SHELXS-97) and additional atoms were located in the difference Fourier map and refined on F2 (SHELXL-97) using the SHELXTL²⁶ and Wingx²⁷ packages. The CHN elemental analyses were performed on a Perkin-Elmer 2400 CHN elemental analyzer (Federal University of Rio Grande do Sul, UFRGS/ Brazil). Statistical treatments of analgesic data were carried out by one-way ANOVA followed by Student-Newman-Keuls test.

General procedure for synthesis of 4-alkoxy-2-oxo-but(pent)-3-enoic acid ethyl esters **2a,f**

To a stirred solution of ethyl oxalyl chloride (2.34 ml, 21 mmol) in dry CHCl₃ (20 mL) at 0°C, a solution of enol ether **1** (20 mmol), CHCl₃ (15 mL) and pyridine (1.7 ml, 21 mmol) was added dropwise. The mixture was left to cool for at least 2 h and then was allowed to gradually warm to room temperature and then stirred for 16h to afford the compounds **2f**. The acylation of metoxypropene (**1b**) required heating at 35°C for 18 h. After this time, the mixture was washed with a solution of H₂O: HCl (10:1) (2 × 10 mL), and with distilled water (2 × 10 mL). The crude products (**2a,f**) were obtained with satisfactory purity and were used without additional purification.

General procedure for synthesis of (*E*)-4-aryl-4-methoxy-2-oxo-but-3-enoic acid ethyl esters **2b-e**

To a stirred solution of ethyl oxalyl chloride (4.6 ml, 41 mmol) in dry CHCl₃ (25 mL) at 0°C, a solution containing the acetal **1** (20 mmol), CHCl₃ (15 mL) and pyridine (3.25 ml, 41 mmol) was added dropwise. The mixture was left to cool for at least 1 h, then was allowed to warm to room temperature and refluxed for 5h. The remaining workup was done as already described for compounds **2a,f**. After the solvent had evaporated the residue was distilled under vacuum to

afford product **2**. The methyl ethyl oxalylate formed during the course of the reaction was distilled at 50 °C (6.2 mbar).

(E)-4-Methoxy-2-oxo-pent-3-enoic acid ethyl ester (2a). Yield: 18.4 mmol (92%); oil; For IR ^1H and ^{13}C NMR and MS data see ref. 11b. Anal. Calcd. for $\text{C}_8\text{H}_{12}\text{O}_4$: C, 55.81; H, 7.02. Found: C, 55.67; H, 6.88.

(E)-4-Methoxy-2-oxo-4-phenyl-but-3-enoic acid ethyl ester (2b). Yield: 16.0 mmol (80%); bp 169-171°C (6.0 mbar); IR (film, ν , cm^{-1}): 2984, 1732, 1684, 1646, 1285, 1190, 1081, 765; ^1H NMR (200 MHz, CDCl_3): δ 1.24 (t, 3H, O-C- CH_3), 3.94 (s, 3H, O- CH_3), 4.04 (q, 2H, O- CH_2), 6.17 (s, 1H, H-3), 7.33-7.48 (m, 5H, Ph); ^{13}C NMR (50 MHz, CDCl_3): δ 13.5 (O-C- CH_3), 56.8 (O- CH_3), 61.6 (O- CH_2), 96.9 (C-3), 127.6, 128.8, 130.5, 133.9 (Ph), 163.2 (C-1), 175.5 (C-4), 181.8 (C-2); MS: m/z % = 234 (M^+ , 1), 161 (100), 131 (9), 115 (79), 105 (54), 77 (76), 59 (56); Anal. Calcd. for $\text{C}_{13}\text{H}_{14}\text{O}_4$: C, 66.66; H, 6.02. Found: C, 66.35; H, 5.59.

(E)-4-(4-Methylphenyl)-4-methoxy-2-oxo-but-3-enoic acid ethyl ester (2c). Yield: 14.0 mmol (70%); bp 180-182°C (6.0 mbar); IR (KBr, ν , cm^{-1}): 3056, 1728, 1680, 1629, 1588, 1273, 1197, 747; ^1H NMR (200 MHz, CDCl_3): δ 1.24 (t, 3H, O-C- CH_3), 2.37 (s, 3H, 4-Me- C_6H_4), 3.92 (s, 3H, O- CH_3), 4.04 (q, 2H, O- CH_2), 6.13 (s, 1H, H-3), 7.18-7.38 (m, 4H, C_6H_4); ^{13}C NMR (50 MHz, CDCl_3): δ 13.4 (O-C- CH_3), 21.0 (4-Me- C_6H_5), 56.6 (O- CH_3), 61.5 (O- CH_2), 96.6 (C-3), 128.2, 128.8, 130.9, 140.9 (C_6H_4), 163.2 (C-1), 175.6 (C-4), 181.8 (C-2); MS: m/z % = 248 (M^+ , 1), 175 (100), 132 (12), 115 (75), 91 (78), 59 (39); Anal. Calcd. for $\text{C}_{14}\text{H}_{16}\text{O}_4$: C, 67.73; H 6.50. Found: C, 67.41; H, 6.36.

(E)-4-(4-Bromophenyl)-4-methoxy-2-oxo-but-3-enoic acid ethyl ester (2d). Yield: 12.4 mmol (62%); mp 68-70°C; bp 196-198°C (5.9 mbar); IR (KBr, ν , cm^{-1}): 2993, 1719, 1674, 1549, 1293, 1141, 1080, 764; ^1H NMR (200 MHz, CDCl_3): δ (J , Hz) 1.30 (t, 3H, O-C- CH_3), 3.94 (s, 3H, O- CH_3), 4.16 (q, 2H, O- CH_2), 6.28 (s, 1H, H-3), 7.35 (d, 2H, $J = 9$, C_6H_4), 7.52 (d, 2H, $J = 9$, C_6H_4); ^{13}C NMR (50 MHz, CDCl_3): δ 13.7 (O-C- CH_3), 57.0 (O- CH_3), 62.0 (O- CH_2), 96.5 (C-3), 125.1, 130.5, 130.9, 132.8 (C_6H_4), 163.0 (C-1), 174.3 (C-4), 180.7 (C-2); MS: m/z % = 314 (M^+ , 1), 241 (100), 183 (43), 160 (30), 116 (82), 89 (88), 59 (90); Anal. Calcd. for $\text{C}_{13}\text{H}_{13}\text{BrO}_4$: C, 49.86; H 4.18. Found: C, 49.60; H, 3.91.

(E)-4-(4-Fluorophenyl)-4-methoxy-2-oxo-but-3-enoic acid ethyl ester (2e). Yield: 16.8 mmol (84%); mp 45-47°C; bp 174-176°C (6.8 mbar); IR (KBr, ν , cm^{-1}): 2984, 1721, 1675, 1282, 1226, 1081, 774; ^1H NMR (200 MHz, CDCl_3): δ 1.29 (t, 3H, O-C- CH_3), 3.94 (s, 3H, O- CH_3), 4.15 (q, 2H, O- CH_2), 6.26 (s, 1H, H-3), 7.02-7.54 (m, 4H, C_6H_4); ^{13}C NMR (50 MHz, CDCl_3): δ ($J_{\text{C-F}}$, Hz) 13.5 (O-C- CH_3), 56.8 (O- CH_3), 61.8 (O- CH_2), 96.2 (C-3), 114.6 (d, $^2J = 22$, C_6H_4), 129.8 (d, $^4J = 3$, C_6H_4), 131.2 (d, $^3J = 9$, C_6H_4), 163.0 (C-1), 163.8 (d, $^1J = 251$, C_6H_4), 174.3 (C-4), 180.7 (C-2); MS: m/z % = 252 (M^+ , 1), 179 (100), 149 (9), 133 (33), 123 (58), 95 (48), 59 (76); Anal. Calcd. for $\text{C}_{13}\text{H}_{13}\text{FO}_4$: C, 61.90; H, 5.19. Found: C, 61.60; H, 4.98.

(E)-4-Ethoxy-3-methyl-2-oxo-but-3-enoic acid ethyl ester (2f). Yield: 13.6 mmol (68%); oil; IR (film, ν , cm^{-1}): 2985, 1735, 1625, 1218, 1050, 1016, 720; ^1H NMR (200 MHz, CDCl_3): δ 1.37 (t, 3H, O-C- CH_3), 1.38 (t, 3H, R^2), 1.93 (s, 3H, CH_3), 4.19 (q, 2H, O- CH_2), 4.33 (q, 2H, O- CH_2), 7.59 (s, 1H, H-3) ^{13}C NMR (50 MHz, CDCl_3): δ 7.1 (R^2), 13.6 (CH_3 , ethyl ester), 15.0 (CH_3 ,

ethoxy), 61.7 (OCH₂, ethyl ester), 71.2 (OCH₂, ethoxy), 127.0 (C-3), 164.0 (C-1), 165.8 (C-4), 186.2 (C-2); MS: *m/z* % = 186 (M⁺, 1), 113 (54), 85 (100), 55 (17); Anal. Calcd. for C₉H₁₄O₄: C, 58.05; H, 7.58. Found: C, 57.76; H, 7.55.

General procedure for synthesis of 5-Hydroxy-4,5-dihydro-1*H*-pyrazoles 6a-f, 7a-f

A mixture of 4-alkoxy-4-alkyl(aryl)-2-oxo-but-3-enoic acid ethyl esters **2** (5 mmol) or 4-alkoxy-4-alkyl(aryl)-1,1,1-trifluoro-3-buten-2-ones **5** (5 mmol) and salicylic hydrazide **4** (912 mg, 6 mmol) was stirred under reflux in dry methanol or ethanol (30 mL) for 16 h. After the mixture was cooled to room temperature the mixture was diluted with water (20 mL) and extracted with CH₂Cl₂ (3 × 30 mL). The combined organic layers were dried over Na₂SO₄, and evaporated under vacuum. Recrystallization from a mixture of hexane/EtOAc (10:1) afforded the pure 5-hydroxy-4,5-dihydro-1*H*-pyrazoles **6**, **7**.

Ethyl 5-hydroxy-3-methyl-1-(2-hydroxybenzoyl)-4,5-dihydro-1*H*-pyrazole-5-carboxylate (6a). Yield: 3.25 mmol (65%); mp 124-126°C; ¹H NMR (200 MHz, CDCl₃): δ (*J*, Hz) 1.28 (t, 3H, O-C-CH₃), 2.16 (s, 3H, R¹), 2.97 (d, 1H, *J* = 18, H-4a), 3.20 (d, 1H, *J* = 18, H-4b), 4.27-4.40 (m, 2H, O-CH₂), 6.83-6.98 (m, 2H, Benzoyl), 7.36-7.44 (m, 1H, Benzoyl), 8.43-8.47 (m, 1H, Benzoyl); ¹³C NMR (50 MHz, DMSO-*d*6): δ 13.9 (CH₃), 15.4 (R¹), 49.4 (C-4), 61.3 (OCH₂), 88.0 (C-5), 116.2, 118.2, 120.7, 129.1, 131.5, 155.4 (Benzoyl), 156.3 (C=O, Benzoyl), 165.2 (CO₂Et), 169.3 (C-3); MS: *m/z* % = 292 (M⁺, 14), 219 (11), 201 (77), 177 (15), 121 (100), 99 (98), 65 (51); Anal. Calcd. for C₁₄H₁₆N₂O₅: C, 57.53; H, 5.52; N, 9.58. Found: C, 57.14; H, 5.17; N, 9.75.

Ethyl 5-hydroxy-3-phenyl-1-(2-hydroxybenzoyl)-4,5-dihydro-1*H*-pyrazole-5-carboxylate (6b). Yield: 3.9 mmol (78%); mp 109-111°C; ¹H NMR (200 MHz, CDCl₃): δ (*J*, Hz) 1.29 (t, 3H, O-C-CH₃), 3.44 (d, 1H, *J* = 18, H-4a), 3.60 (d, 1H, *J* = 18, H-4b), 4.29-4.42 (m, 2H, O-CH₂), 6.93-7.01 (m, 2H, Benzoyl), 7.43-7.50 (m, 5H, Ph), 7.75-7.78 (m, 1H, Benzoyl), 8.60-8.63 (m, 1H, Benzoyl), 11.48 (s, 1H, 2-OH-Benzoyl); ¹³C NMR (50 MHz, DMSO-*d*6): δ 13.9 (CH₃), 45.9 (C4), 61.5 (OCH₂), 88.6 (C5), 116.3, 118.3, 120.3, 131.9, 153.1 (Benzoyl), 126.6, 128.8, 129.5, 130.5 (Ph), 156.7 (C3), 165.7 (C=O, Benzoyl), 169.1 (CO₂Et); MS: *m/z* % = 354 (M⁺, 6), 281 (6), 263 (18), 161 (100), 121 (63), 65 (20); Anal. Calcd. for C₁₉H₁₈N₂O₅: C, 64.40; H, 5.12; N, 7.91. Found: C, 64.34; H, 5.09; N, 7.74.

Ethyl 5-hydroxy-3-(4-methylphenyl)-1-(2-hydroxybenzoyl)-4,5-dihydro-1*H*-pyrazole-5-carboxylate (6c). Yield: 3.65 mmol (73%); mp 116-118°C; ¹H NMR (200 MHz, CDCl₃): δ (*J*, Hz) 1.29 (t, 3H, O-C-CH₃), 2.42 (s, 3H, 4-CH₃-C₆H₅), 3.41 (d, 1H, *J* = 18, H4a), 3.59 (d, 1H, *J* = 18, H-4b), 4.26-4.46 (m, 2H, OCH₂), 6.90-7.02 (m, 2H, Benzoyl), 7.24-7.28 (m, 2H, C₆H₄), 7.40-7.48 (m, 1H, Benzoyl), 7.64 (m, 2H, C₆H₄), 8.60-8.64 (m, 1H, Benzoyl); ¹³C NMR (50 MHz, DMSO-*d*6): δ 13.8 (O-C-CH₃), 21.0 (4-CH₃-C₆H₄), 45.9 (C-4), 61.5 (O-CH₂), 88.6 (C-5), 116.3, 118.3, 120.2, 129.3, 132.0, 153.2 (Benzoyl), 126.6, 127.7, 129.6, 140.4 (C₆H₄), 156.9 (C-3), 165.7 (C=O, Benzoyl), 169.1 (CO₂Et); MS: *m/z* % = 368 (M⁺, 5), 248 (6), 230 (7), 179 (15), 121 (100), 101 (8), 65 (28); Anal. Calcd. for C₂₀H₂₀N₂O₅: C, 65.21; H, 5.47; N 7.60. Found: C, 64.84; H, 5.44; N, 7.56.

Ethyl 3-(4-bromophenyl)-5-hydroxy-1-(2-hydroxybenzoyl)-4,5-dihydro-1H-pyrazole-5-carboxylate (6d). Yield: 4.45 mmol (89%); mp 138-140°C; ¹H NMR (200 MHz, CDCl₃): δ (*J*, Hz) 1.29 (t, 3H, O-C-CH₃), 3.39 (d, 1H, *J* = 18, H-4a), 3.58 (d, 1H, *J* = 18, H-4b), 4.26-4.47 (m, 2H, O-CH₂), 6.88-7.04 (m, 2H, Benzoyl), 7.41-7.49 (m, 1H, Benzoyl), 7.60 (m, 4H, C₆H₄), 8.52-8.57 (m, 1H, Benzoyl); ¹³C NMR (50 MHz, DMSO-*d*₆): δ 13.9 (O-C-CH₃), 45.8 (C-4), 61.6 (O-CH₂), 88.7 (C-5), 116.3, 118.3, 120.6, 129.3, 129.7, 152.1 (Benzoyl), 123.9, 128.3, 128.5, 131.8 (C₆H₄), 156.4 (C-3), 165.8 (C=O, Benzoyl), 169.0 (CO₂Et); MS: *m/z* % = 434 (M⁺, 4), 361 (5), 341 (7), 314 (9), 241 (40), 121 (100), 93 (21), 65 (40); Anal. Calcd. for C₁₉H₁₇BrN₂O₅: C, 52.68; H, 3.96; N, 6.47. Found: C, 52.45; H, 3.94; N, 6.44.

Ethyl 3-(4-fluorophenyl)-5-hydroxy-1-(2-hydroxy benzoyl)-4,5-dihydro-1H-pyrazole-5-carboxylate (6e). Yield: 4.25 mmol (85%); mp 128-130°C; ¹H NMR (200 MHz, CDCl₃): δ (*J*, Hz) 1.29 (t, 3H, O-C-CH₃), 3.40 (d, 1H, *J* = 18, H-4a), 3.59 (d, 1H, *J* = 18, H-4b), 4.23-4.47 (m, 2H, O-CH₂), 6.91-7.01 (m, 2H, Benzoyl), 7.11-7.20 (m, 2H, C₆H₄), 7.40-7.49 (m, 1H, Benzoyl), 7.72-7.79 (m, 2H, C₆H₄), 8.54-8.58 (m, 1H, Benzoyl); ¹³C NMR (100 MHz, DMSO-*d*₆): δ (*J*_{C-F}, Hz) 13.9 (CH₃), 46.0 (C-4), 61.6 (OCH₂), 88.7 (C-5), 115.9 (d, ²*J* = 22, C₆H₄), 127.2 (d, ⁴*J* = 3), 129.0 (d, ³*J* = 8), 163.3 (d, ¹*J* = 248), 116.3, 118.3, 120.6, 129.6, 131.9, 152.2 (Benzoyl), 156.5 (C-3), 165.8 (C=O, Benzoyl), 169.1 (CO₂Et); MS: *m/z* % = 372 (M⁺, 10), 299 (10), 281 (25), 252 (24), 179 (100), 121 (100), 93 (33), 65 (65); Anal. Calcd. for C₁₉H₁₇FN₂O₅: C, 61.29; H, 4.60; N, 7.52. Found: C, 61.31; H, 4.42; N, 7.43.

Ethyl 5-Hydroxy-4-methyl-1-(2-hydroxybenzoyl)-4,5-dihydro-1H-pyrazole-5-carboxylate (6f). Yield: 3.0 mmol (60%); mp 88-90°C; ¹H NMR (200 MHz, CDCl₃): δ (*J*, Hz) 1.22-1.42 (m, 3H, O-C-CH₃), 1.30 (d, 3H, *J* = 7, R²), 3.41 (qd, *J* = 7, *J* = 1, H-4), 4.25-4.44 (m, 2H, OCH₂), 6.87 (qd, *J* = 7, *J* = 1, 1H, H-3), 6.95-6.99 (m, 2H, Benzoyl), 7.37-7.45 (m, 1H, Benzoyl), 8.33-8.38 (m, 1H, Benzoyl); ¹³C NMR (50 MHz, DMSO-*d*₆): δ 8.9 (R²), 13.9 (O-C-CH₃), 50.0 (C-4), 61.5 (O-CH₂), 87.5 (C-5), 116.1, 118.2, 121.3, 129.0, 131.4, 151.1 (Benzoyl), 155.8 (C-3), 166.0 (C=O, Benzoyl), 167.9 (CO₂Et); MS: *m/z* % = 292 (M⁺, 10), 219 (13), 201 (71), 163 (38), 121 (100), 93 (58), 65 (100); Anal. Calcd. for C₁₄H₁₆N₂O₅: C, 57.53; H, 5.52; N, 9.58. Found: C, 57.68; H, 5.84; N, 9.69.

5-Hydroxy-3-methyl-5-trifluoromethyl-4,5-dihydro-1H-1-(2-hydroxybenzoyl)pyrazole (7a). Yield: 4.5 mmol (90%); mp 74-76°C; ¹H NMR (200 MHz, CDCl₃): δ (*J*, Hz) 2.11 (s, 3H, R¹), 3.12 (d, 1H, *J* = 19, H-4a), 3.31 (d, 1H, *J* = 19, H-4b), 6.55 (s, 1H, OH), 6.84-7.00 (m, 2H, Benzoyl), 7.38-7.47 (m, 1H, Benzoyl), 8.14-8.19 (m, 1H, Benzoyl), 10.69 (s, 1H, 2-OH-Benzoyl); ¹³C NMR (50 MHz, DMSO-*d*₆): δ (*J*_{C-F}, Hz) 15.2 (CH₃), 47.8 (C-4), 90.8 (q, ²*J* = 34, C5), 115.9, 118.3, 124.3, 128.2, 130.7, 153.7 (Benzoyl), 123.5 (q, ¹*J* = 286, CF₃), 153.5 (C-3), 167.0 (C=O); MS: *m/z* % = 288 (M⁺, 19), 177 (9), 121 (100), 93 (20), 65 (38); Anal. Calcd. for C₁₂H₁₁F₃N₂O₃: C, 50.01; H, 3.85; N, 9.72. Found: C, 50.03; H, 3.57; N, 9.65.

5-Hydroxy-3-phenyl-5-trifluoromethyl-4,5-dihydro-1H-1-(2-hydroxybenzoyl)pyrazole (7b). Yield: 4.8 mmol (96%); mp 114-116°C; ¹H NMR (200 MHz, CDCl₃): δ (*J*, Hz) 3.55 (d, 1H, *J* = 19, H4a), 3.75 (d, 1H, *J* = 19, H4b), 6.91-7.03 (m, 2H, Benzoyl), 7.42-7.50 (m, 5H, Ph), 7.67-7.72 (m, 1H, Benzoyl), 8.30-8.35 (m, 1H, Benzoyl), 10.78 (br, 1H, 2-OH-Benzoyl); ¹³C NMR

(50 MHz, DMSO-*d*6): δ (J_{C-F} , Hz) 44.4 (C-4), 91.7 (q, $^2J = 34$, C-5), 116.0, 118.4, 123.9, 128.7, 130.6, 151.4 (Benzoyl), 123.6 (q, $^1J = 286$, CF₃), 126.6, 128.8, 130.4, 131.2 (Ph), 155.1 (C-3), 167.4 (C=O); MS: m/z % = 350 (M⁺, 49.5), 230 (89), 213 (71), 161 (100), 138 (20), 121 (100), 93 (69), 65 (88); Anal. Calcd. for C₁₇H₁₃F₃N₂O₃: C, 58.29; H, 3.74; N, 8.00. Found: C, 57.97; H, 3.72; N, 7.95.

5-Hydroxy-3-(4-methylphenyl)-5-trifluoromethyl-4,5-dihydro-1H-1-(2-hydroxybenzoyl)pyrazole (7c). Yield: 4.56 mmol (91%); mp 123-125°C; ¹H NMR (200 MHz, CDCl₃): δ (J , Hz) 2.40 (4-CH₃-C₆H₄), 3.53 (d, 1H, $J = 19$, H-4a), 3.73 (d, 1H, $J = 19$, H-4b), 6.55 (s, 1H, OH), 6.90-7.04 (m, 2H, Benzoyl), 7.23-7.27 (m, 2H, C₆H₄), 7.42-7.51 (m, 1H, Benzoyl), 7.57-7.61 (m, 2H, C₆H₄), 8.31-8.36 (m, 1H, Benzoyl), 10.80 (s, 1H, 2-OH-Benzoyl); ¹³C NMR (100 MHz, DMSO-*d*6): δ (J_{C-F} , Hz) 21.0 (4-CH₃-C₆H₄), 44.4 (C-4), 91.5 (q, $^2J = 34$, C-5), 115.9, 118.3, 124.0, 128.6, 131.0, 151.3 (Benzoyl), 123.5 (q, $^1J = 286$, CF₃), 126.5, 127.6, 129.3, 140.4 (C₆H₄), 154.9 (C-3), 167.2 (C=O); MS: m/z % = 364 (M⁺, 9), 244 (40), 226 (25), 175 (59), 121 (100), 65 (30); Anal. Calcd. for C₁₈H₁₅F₃N₂O₃: C, 59.34; H, 4.15; N, 7.69. Found: C, 58.99; H, 3.74; N, 7.58.

3-(4-Bromophenyl)-5-hydroxy-5-trifluoromethyl-4,5-dihydro-1H-1-(2-hydroxybenzoyl)pyrazole (7d). Yield: 4.47 mmol (89%); mp 131-133°C; ¹H NMR (200 MHz, CDCl₃): δ (J , Hz) 3.52 (d, 1H, $J = 19$, H-4a), 3.72 (d, 1H, $J = 19$, H-4b), 6.54 (br, 1H, OH), 6.91-7.04 (m, 2H, Benzoyl), 7.43-7.52 (m, 1H, Benzoyl), 7.57-7.62 (m, 4H, C₆H₄), 8.24-8.28 (m, 1H, Benzoyl), 10.70 (s, 1H, 2-OH-Benzoyl); ¹³C NMR (50 MHz, DMSO-*d*6): δ (J_{C-F} , Hz) = 44.2 (C-4), 91.7 (q, $^2J_{C-F} = 34$, C-5), 115.8, 118.3, 124.0, 128.5, 131.1, 150.5 (Benzoyl), 123.3 (q, $^1J = 286$ Hz, CF₃), 128.3, 129.5, 131.8 (C₆H₄), 154.8 (C-3), 167.1 (C=O); MS: m/z % = 428 (M⁺, 29), 308 (76), 292 (62), 239 (74), 138 (43), 121 (100), 93 (85), 65 (89); Anal. Calcd. for C₁₇H₁₂BrF₃N₂O₃: C, 47.57; H, 2.82; N, 6.53. Found: C, 47.33; H, 2.67; N, 6.35.

3-(4-Fluorophenyl)-5-hydroxy-5-trifluoromethyl-4,5-dihydro-1H-1-(2-hydroxybenzoyl)pyrazole (7e). Yield: 4.27 mmol (85%); mp 122-124°C; ¹H NMR (200 MHz, CDCl₃): δ (J , Hz) 3.53 (d, 1H, $J = 19$, H-4a), 3.73 (d, 1H, $J = 19$, H-4b), 6.54 (s, 1H, OH), 6.91-7.04 (m, 2H, Benzoyl), 7.10-7.19 (m, 2H, C₆H₄), 7.43-7.52 (m, 1H, Benzoyl), 6.67-7.74 (m, 2H, C₆H₄), 8.26-8.31 (m, 1H, Benzoyl), 10.72 (s, 1H, 2-OH-Benzoyl); ¹³C NMR (50 MHz, DMSO-*d*6): δ (J_{C-F} , Hz) 44.4 (C-4), 91.7 (q, $^2J = 35$ Hz, C-5), 115.9 (d, $^2J = 22$ Hz, C₆H₄), 126.9 (d, $^4J = 3$ Hz, C₆H₄), 128.9 (d, $^3J = 9$ Hz, C₆H₄), 163.4 (d, $^1J = 249$ Hz, C₆H₄), 123.4 ($^1J = 286$ Hz, CF₃), 115.9, 118.4, 124.0, 128.6, 131.1, 150.5 (Benzoyl), 154.9 (C-3), 167.2 (C=O); MS: m/z % = 368 (M⁺, 34), 248 (62), 230 (46), 179 (91), 138 (36), 121 (100), 93 (84), 65 (97); Anal. Calcd. for C₁₇H₁₂F₄N₂O₃: C, 55.44; H, 3.28; N, 7.61. Found: C, 55.44; H, 3.09; N, 7.62.

5-Hydroxy-4-methyl-5-trifluoromethyl-4,5-dihydro-1H-1-(2-hydroxybenzoyl)pyrazole (7f). Yield: 4.36 mmol (87%); mp 83-85°C; ¹H NMR (200 MHz, CDCl₃): δ (J , Hz) 1.30 (d, 3H, $J = 7$, R²), 3.48 (qd, $J = 7$ Hz, $J = 1$ Hz, H-4), 6.54 (s, 1H, OH), 6.85-7.01 (m, 2H, Benzoyl), 6.97 (s, 1H, H-3), 7.39-7.47 (m, 1H, Benzoyl), 8.04-8.09 (m, 1H, Benzoyl), 10.52 (s, 1H, 2-OH-Benzoyl); ¹³C NMR (50 MHz, DMSO-*d*6): δ (J_{C-F} , Hz) 9.5 (CH₃), 48.3 (C-4), 89.9 (q, $^2J_{C-F} = 33$, C-5), 115.8, 118.3, 124.2, 128.2, 130.7, 149.6 (Benzoyl), 123.7 (q, $^1J = 286$ Hz, CF₃), 154.4 (C-

3), 167.8 (C=O); MS: m/z % = 288 (M^+ , 20), 163 (39), 121 (100), 93 (30), 65 (47); Anal. Calcd. for $C_{12}H_{11}F_3N_2O_3$: C, 50.01; H, 3.85; N, 9.72. Found: C, 50.31; H, 3.97; N, 9.75.

Acknowledgements

The authors thank the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq/PRONEX) and Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS) for financial support, as well as Dr. R. A. Burrow, for solving the crystal structures. Fellowships from CNPq and CAPES are also acknowledged.

References and Notes

- (a) Elguero, J. In: *Comprehensive Heterocyclic Chemistry II*, Vol. 3; Katritzky, A. R.; Rees, C. W.; Scriven, E. F. V., Eds.; Pergamon: Oxford, 1996, 1. (b) Katritzky, A. R.; Wang, M.; Zhang, S.; Voronkov, M. V. *J. Org. Chem.* **2001**, *66*, 6787; and references therein.
- (a) Kees, K. L.; Fitzgerald, J. J. Jr.; Steiner, K. E.; Mattes, J. F.; Mihan, B.; Tosi, T.; Mondoro, D.; McCaleb, M. L. *J. Med. Chem.* **1996**, *39*, 3920. (b) Genin, M. J.; Biles, C.; Keiser, B. J.; Poppe, S. M.; Swaney, S. M.; Tarpley, W. G.; Yagi, Y.; Romero, D. L. *J. Med. Chem.* **2000**, *43*, 1034. (c) Manfredini, S.; Bazzanini, R.; Baraldi, P. G.; Guarneri, M.; Simoni, D.; Marongiu, M. E.; Pani, A.; Tramontano, E.; Colla, P. L. *J. Med. Chem.* **1992**, *35*, 917. (d) Jungheim, L. N. *Tetrahedron Lett.* **1989**, *30*, 1889. (e) Dannhardt, G.; Laufer, S. *Curr. Med. Chem.* **2000**, *7*, 1101. (f) Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. *J. Med. Chem.* **1997**, *40*, 1347.
- Vane, J. R. *Nat. New. Biol.* **1971**, *231*, 232. (b) Campos, C.; Gregorio, R.; García-Neto, R.; Gago, F.; Ortiz, P.; Alamany, S. *Eur. J. Pharmacol.* **1999**, *378*, 339.
- Tortorici, V.; Vasquez, E.; Venegas, H. *Brain Res.* **1996**, *725*, 106.
- Lorenzetti, B. B.; Ferreira, S. H. *Inflamm. Res.* **1996**, *45*, 308.
- Beirith, A.; Santos, A. R. S.; Rodrigues, A. L. S.; Creczynsky-pasa, T. B.; Calixto, J. B. *Eur. J. Pharmacol.* **1998**, *345*, 233.
- (a) Martins, M. A. P.; Cunico, W.; Pereira, C. M. P.; Sinhoin, A. P.; Flores, A. F. C.; Bonacorso, H. G.; Zanatta, N. *Curr. Org. Synthesis* **2004**, *1*, 391; and references therein. (b) Martins, M. A. P.; Pereira, C. M. P.; Moura, S.; Fiss, G. F.; Frizzo, C. P.; Emmerich, D. J.; Zanatta, N.; Bonacorso, H. G. *ARKIVOC* **2006**, (xiii), 187.
- (a) Spiegler, W.; Götz, N. *Synthesis* **1986**, 69. (b) Martins, M. A. P.; Flores, A. F. C.; Bastos, G. P.; Sinhoin, A.; Bonacorso, H. G.; Zanatta, N. *Tetrahedron Lett.* **2000**, *41*, 293. (c)

- Martins, M. A. P.; Freitag, R.; Flores, A. F. C.; Zanatta, N. *Synthesis* **1995**, 1491.
9. Martins, M. A. P.; Freitag, R. A.; Rosa, A.; Flores, A. F. C.; Zanatta, N.; Bonacorso, H. G. *J. Heterocycl. Chem.* **1999**, *36*, 217.
 10. (a) Palacios, F.; Retana, A. M. O.; Pagalday, J. *Tetrahedron* **1999**, *55*, 14451. (b) Padwa, A.; MacDonald, J. G. *J. Heterocycl. Chem.* **1987**, *24*, 1225. (c) Padwa, A.; Kulkarni, Y.; Zhang, Z. *J. Org. Chem.* **1990**, *55*, 4144.
 11. (a) Tietze, L. F.; Meier, H.; Voß, E. *Synthesis* **1988**, 274. (b) Haider, A.; Wyler, H. *Helvet. Chim. Acta* **1983**, *66*, 606. (c) Croxall, W. J.; Schneider, H. J. Patent 2550042: *Chem. Abstr.* **1951**, *45*, 50056.
 12. (a) Souza, F. R.; Figuera, M. R.; Lima, T. T. F.; Bastiani, J.; Barcellos, I. B.; Almeida, C. E.; Oliveira, M. R.; Bonacorso, H. G.; Flores, A. E.; Mello, C. F. *Pharm. Biochem. Behav.* **2001**, *68*, 525. (b) Godoy, M. C. M.; Figuera, M. R.; Souza, F. R.; Flores, A. E.; Rubin, M. A.; Oliveira, M. R.; Zanatta, N.; Martins, M. A. P.; Bonacorso, H. G.; Mello, C. F. *Eur. J. Pharmacol.* **2004**, *496*, 93. (c) Souza, F. R.; Ratzlaff, V. T.; Borges, L. P.; Oliveira, M. R.; Bonacorso, H. G.; Zanatta, N.; Martins, M. A. P.; Mello, C. F. *Eur. J. Pharmacol.* **2002**, *451*, 141. (d) Tomazetti, J.; Ávila, D. S.; Ferreira, A. P. O.; Martins, J. S.; Souza, F. R.; Royer, C.; Rubin, M. A.; Oliveira, M. R.; Bonacorso, H. G.; Martins, M. A. P.; Zanatta, N.; Mello, C. F. *J. Neurosci. Meth.* **2005**, *147*, 29. (e) Tabarelli, Z.; Rubin, M. A.; Berlese, D. B.; Sauzem, P. D.; Missio, T. P.; Teixeira, M. V.; Sinhorin, A. P.; Martins, M. A. P.; Zanatta, N.; Bonacorso, H. G.; Mello, C. F. *Braz. J. Med. Biol. Res.* **2004**, *37*, 1531.
 13. Lazar, C.; Kluczyk, A.; Kiota, T.; Konishi, Y. *J. Med. Chem.* **2004**, *47*, 6973.
 14. Martins, M. A. P.; Bastos, G. P.; Bonacorso, H. G.; Zanatta, N.; Flores, A. F. C.; Siqueira, G. M. *Tetrahedron Lett.* **1999**, *40*, 4309.
 15. Wohl, R. A. *Synthesis* **1974**, 38.
 16. Gypser, A.; Kirstgen, R.; Sauter, H.; Bayer, H.; Cullmann, O.; Gewehr, M.; Grammenos, W.; Muller, B.; Ptock, A.; Blasco, J. T.; Ammermann, E.; Grote, T.; Lorenz, G.; Strathmann, S. PCT Int. Appl. 2000020399: *Chem. Abstr.* **2000**, *132*, 279215.
 17. (a) Lin, P.; Jiang, J. *Tetrahedron* **2000**, *56*, 3635. (b) Arnone, A.; Bernardi, R.; Blasco, F.; Cardillo, R.; Resnati, G.; Gerus, I. I.; Kukhar, V. P. *Tetrahedron* **1998**, *54*, 2809.
 18. Farrugia, L. J. *J. Appl. Crystallogr.* **1997**, *30*, 565.
 19. Khan, K. M.; Rasheed, M.; Zia-Ullah; Hayat, S.; Kaukab, F.; Choudhary, M. I.; Atta-ur-Rahman; Perveen, S. *Bioorg. Med. Chem.* **2003**, *11*, 1381.
 20. (a) Martins, M. A. P.; Colla, A.; Fischer, P.; Krimmer, S. *Synthesis* **1991**, 483. (b) Bonacorso, H. G.; Lopes, I. S.; Wastowski, A. D.; Zanatta, N.; Martins, M. A. P. *J. Fluorine Chem.* **2003**, *120*, 29.
 21. (a) Dewar, M. J. S.; Zoebisch, E. G.; Healey, E. F.; Stewart, J. J. P. *J. Am. Chem. Soc.* **1985**, *107*, 3902. (b) HyperChem Hypercube, Inc., Waterloo, Ontario, Canada, 2002.
 22. Martins, M. A. P.; Flores, A. F. C.; Freitag, R. A.; Zanatta, N.; Hörner, M.; Bortoluzzi, A. J. *Spectrosc. Lett.* **1997**, *30*, 661.
 23. Full crystallographic data for structures reported in this paper have been deposited with the

Cambridge Crystallographic Data Center. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (Fax: +44-01223-336033) or via www.cam.ac.uk/datarequest/cif.

24. Hayashi, G.; Takemori, A. E. *Eur. J. Pharmacol.* **1971**, *16*, 63.
25. Perrin, D. D.; Armarego, W. L. F. In *Purification of Laboratory Chemicals*; Pergamon: Oxford, 1998.
26. *SHELXTL 6.14*; Bruker AXS Inc.: Madison WI, **2003**.
27. Farrugia, L. J. *J. Appl. Crystallogr.* **1999**, *32*, 837.